Host modulation therapy: An indispensable part of perioceutics

Journal of Indian Society of Periodontology

Volumn 18, Issue 3, 2014, Pages 282-288

  Gulati, Minkle ^a   Anand, Vishal ^b   Govila, Vivek ^a   Jain, Nikil ^c  

^a BABU BANARASI DAS NATIONAL INSTITUTE OF TECHNOLOGY AND MANAGEMENT   (India)

^b KING GEORGE'S MEDICAL UNIVERSITY   (India)

^c Vinayaka Mission's Sankarachariyar Dental College   (India)

Author keywords

Bisphosphonate; host modulation; locally delivered; nonsteroidal anti inflammatory drugs; perioceutics; periodontitis; systemically delivered; tetracycline

Indexed keywords

EID: 84903785143     PISSN: 0972124X     EISSN: 09751580     Source Type: Journal    
DOI: 10.4103/0972-124X.134559     Document Type: Review

References (82)

1. Haffajee AD, Socransky SS. Microbial etiologic agents of destructive periodontal diseases. Periodontol 2000 1994;5:78-111.
2. Ryan ME, Preshaw PM. Host Modulation. In: Newman MG, Takei HH, Klollevold PR, Carranza FA, editors. Carranza's Clinical Periodontology. 11 th ed. India: Saunders; 2012. p. 275-280.
3. Kirkwood KL, Cirelli JA, Rogers JE, Giannobile WV. Novel host response therapeutic approaches to treat periodontal diseases. Periodontol 2000 2007;47:294-315.
4. Preshaw PM. Host response modulation in periodontics. Periodontol 2000 2008;48:92-110.
5. Giannobile WV. Host-Response Therapeutics for Periodontal Diseases. J Periodontol 2008;79:1592-600.
6. Souza JA, Rossa C Jr, Garlet GP, Nogueira AV, Cirelli JA. Modulation of host cell signaling pathways as a therapeutic approach in periodontal disease. J Appl Oral Sci 2012;20:128-38.
7. Information Paper. The pathogenesis of periodontal diseases. J Periodontol 1999;70:457-70.
8. Thomson RG. Modulating the host response as an adjunctive treatment for periodontitis. Periodontology 2001;22:26-34.
9. Williams RC. Periodontal disease. N Engl J Med 1990;322:373-82. (Pubitemid 20042743)
10. Golub LM, Suomalainen K, Sorsa T. Host modulation with tetracyclines and their chemically modified analogues. Curr Opin Dent 1992;2:80-90.
11. Kantarci A, Hasturk H, Van Dyke TE. Host-mediated resolution of inflammation in periodontal diseases. Periodontol 2000 2006;40:144-63. (Pubitemid 43434247)
12. Assisting with periodontics (Chapter 9). In: Kesel LM, editor. Veterinary dentistry for the small animal technician. 1 st ed. Hoboken: Wiley; 2013.
13. Available from: http://trademarks.breanlaw.com/75537686-perioceutic.html [Last accessed on 2013 Oct 20]
14. Ryan ME. Host modulation: conceptualization to clinical trials and integration into clinical practice J. Candian Assoc 2002;6:1-8
15. Honibald EN, Mathew S, Padmanaban IJ, Sundaram E, Ramamoorthy RD. Perioceutics: Matrix metalloproteinase inhibitors as an adjunctive therapy for inflammatory periodontal disease. J Pharm Bioallied Sci 2012;4:S417-21.
16. Ryan ME. Nonsurgical approaches for the treatment of periodontal diseases. Dent Clin N Am 2005;49:611-36. (Pubitemid 40835776)
17. Lawrence T, Willoughby DA, Gilroy DW. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol 2002;2:787-95. (Pubitemid 37328718)
18. Serhan CN. A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution. Histochem Cell Biol 2004;122:305-21. (Pubitemid 39506589)
19. Ryan ME, Golub LM. Modulation of matrix metalloproteinase activities in periodontitis as a treatment strategy. Periodontol 2000 2000;24:226-38.
20. Caton J, Ciancio S, Crout R, Hefti A, Polson A. Adjunctive use of subantimicrobial doxycycline therapy for periodontitis. J Dent Res 1998;77:1001.
21. Sapadin AN, Fleischmajer R. Tetracyclines: Nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006;54:258-65. (Pubitemid 43144395)
22. Golub LM, Lee HM, Lehrer G, Nemiroff A, McNamara TF, Kaplan R, et al. Minocycline reduces gingival collagenolytic activity during diabetes: Preliminary observations and a proposed new mechanism of action. J Periodontal Res 1983;18:516-26. (Pubitemid 14221747)
23. Golub LM, Wolff M, Lee HM, McNamara TF, Ramamurthy NS, Zambon J, et al. Further evidence that tetracyclines inhibit collagenase activity in human crevicular fluid and from other mammalian sources. J Periodontal Res 1985;20:12-23. (Pubitemid 15101424)
24. Golub LM, McNamara TF, D'Angelo G, Greenwald RA, Ramamurthy NS. A non-antibacterial chemically modified tetracycline inhibits mammalian collagenase activity. J Dent Res 1987;66:1310-4. (Pubitemid 17127109)
25. McNamara TF, Golub LM, D'Angelo G, Ramamurthy NS. The synthesis and characterization of a non-antibacterial chemically-modified tetracycline (CMT). J Dent Res 1986;65:266.
26. Weaks-Dybvig M, Sanavi F, Zander H, Rifkin BR. The effect of indomethacin on alveolar bone loss in experimental periodontitis. J Periodontal Res 1982;17:90-100. (Pubitemid 12152437)
27. Heasman PA, Offenbacher S, Collins JG, Edwards G, Seymour RA. Flurbiprofen in the prevention and treatment of experimental gingivitis. J Clin Periodontol 1993;20:732-8. (Pubitemid 23331691)
28. Nyman S, Schroeder HE, Lindhe J. Suppression of inflammation and bone resorption by indomethacin during experimental periodontitis in dogs. J Periodontol 1979;50:450-61. (Pubitemid 10248095)
29. Howell TH, Jeffcoat MK, Goldhaber P, Reddy MS, Kaplan ML, Johnson HG, et al. Inhibition of alveolar bone loss in beagles with the NSAID naproxen. J Periodontal Res 1991;26:498-501.
30. Van Dyke TE. Control of inflammation and periodontitis. Periodontology 2000 2007;45:158-66.
31. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008;8:349-61. (Pubitemid 351595216)
32. Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res 2010;107:1170-84.
33. Janakiram NB, Rao CV. Role of lipoxins and resolvins as anti-inflammatory and proresolving mediators in colon cancer. Curr Mol Med 2009;9:565-79.
34. Fredman G, Oh SF, Ayilavarapu S, Hasturk H, Serhan CN, Van Dyke TE. Impaired Phagocytosis in Localized Aggressive Periodontitis: Rescue by Resolvin E1. PLoS One 2011;6:e24422.
35. Grover V, Malhotra R, Kapoor A, Singh J, Sachdeva S. Pro-resolution mediators and receptors: Novel drug targets for enhancing pharmacological armamentarium against periodontal inflammation. Infect Disord Drug Targets 2013;13:75-84.
36. Kohli P, Levy BD. Resolvins and protectins: Mediating solutions to inflammation. Br J Pharmacol 2009;158:960-71.
37. Riccelli AE, Agarwal S, Piesco NP, Hoffman RD, Suzuki JB. Role of cytokines in periodontal diseases. J Calif Dent Assoc 1995;23:48-51.
38. Bartold PM, Cantley MD, Haynes DR. Mechanisms and control of pathologic bone loss in periodontitis. Periodontol 2000 2010;53:55-69.
39. Waykole YP, Doiphode SS, Rakhewar PS, Mhaske M. Anticytokine therapy for periodontal diseases: Where are we now? J Indian Soc Periodontol 2009;13:64-8.
40. Garlet GP, Cardoso CR, Campanelli AP, Martins W Jr, Silva JS. Expression of suppressors of cytokine signaling in diseased periodontal tissues: a stop signal for disease progression? J Periodontal Res 2006;41:580-4. (Pubitemid 44656936)
41. de Souza JA, Nogueira AV, de Souza PP, Cirelli JA, Garlet GP, Rossa C Jr. Expression of suppressor of cytokine signaling 1 and 3 in ligature-induced periodontitis in rats. Arch Oral Biol 2011;56:1120-8.
42. Lima V, Vidal FD, Rocha FA, Brito GA, Ribeiro RA. Effects of tumor necrosis factor-alpha inhibitors pentoxifylline and thalidomide on alveolar bone loss in short-term experimental periodontal disease in rats. J Periodontol 2004;75:162-8. (Pubitemid 38312781)
43. Cochran DL. Inflammation and bone loss in periodontal disease. J Periodontol 2008;79:1569-76.
44. Jin Q, Cirelli JA, Park CH, Sugai JV, Taba M Jr, Kostenuik PJ, et al. RANKL Inhibition Through Osteoprotegerin Blocks Bone Loss in Experimental Periodontitis. J Periodontol 2007;78:1300-8.
45. Martuscelli G, Fiorellini JP, Crohin CC, Howell TH. The effect of interleukin-11 on the progression of ligature-induced periodontal disease in the beagle dog. J Periodontol 2000;71:573-8. (Pubitemid 30602324)
46. Shinoda H, Takeyama S, Suzuki K, Murakami S, Yamada S. Pharmacological topics of bone metabolism: a novel bisphosphonate for the treatment of periodontitis. J Pharmacol Sci 2008;106:555-8. (Pubitemid 351556232)
47. Tenenbaum HC, Shelemay A, Girard B, Zohar R, Fritz PC. Bisphosphonates and periodontics: Potential applications for regulation of bone mass in the periodontium and other therapeutic/diagnostic uses. J Periodontol 2002;73:813-22.
48. Yip RML. Bisphosphonates and Osteonecrosis of the Jaw. Hong Kong Bull Rheum Dis 2008;8:19-25.
49. Shoji K, Horiuchi H, Shinoda H. Inhibitory effects of acbisphosphonate (risedronate) on experimental periodontitis in rats. J Periodontal Res 1995;30:277-84.
50. Inagaki K, Kurosu Y, Sakano M, Yamamoto G, Kikuchi T, Noguchi T, et al. Oral osteoporosis: a review and its dental implications. Clin Calcium 2007;17:157-63.
51. Shu L, Guan SM, Fu SM, Guo T, Cao M, Ding Y. Estrogen modulates cytokine expression in human periodontal ligament cells. J Dent Res 2008;87:142-7.
52. Southan GJ, Szabo C. Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Biochem Pharmacol 1996;51:383-94. (Pubitemid 26071171)
53. Chapple IL. Reactive oxygen species and antioxidants in inflammatory diseases. J Clin Periodontol 1997;24:287-96. (Pubitemid 127731526)
54. Batista AC, Silva TA, Chun JH, Lara VS. Nitric oxide synthesis and severity of human periodontal disease. Oral Dis 2002;8:254-60.
55. Lohinai Z, Benedek P, Feher E, Gyorfi A, Rosivall L, Fazekas A, et al. Protective effects of mercaptoethylguanidine, a selective inhibitor of inducible nitric oxide synthase, in ligature-induced periodontitis in the rat. Br J Pharmacol 1998;123:353-60. (Pubitemid 28059703)
56. Leitao RF, Ribeiro RA, Chaves HV, Rocha FA, Lima V, Brito GA. Nitric oxide synthase inhibition prevents alveolar bone resorption in experimental periodontitis in rats. J Periodontol 2005;76:956-63. (Pubitemid 40903838)
57. Thomas CM, Versalovic J. Probiotics-host communication: Modulation of signaling pathways in the intestine. Gut Microbes 2010;1:148-63.
58. Teughels W, Loozen G, Quirynen M. Do probiotics offer opportunities to manipulate the periodontal oral microbiota? J Clin Periodontol 2011;38:159-77.
59. Hajishengallis G. Toll gates to periodontal host modulation and vaccine therapy. Periodontol 2000 2009;51:181-207.
60. Yokoyama K, Sugano N, Shimada T, Shofiqur RA, Ibrahim el-SM, Isoda R, et al. Effects of egg yolk antibody against Porphyromonas gingivalis gingipains in periodontitis patients. J Oral Sci 2007;49:201-6.
61. Choi J, Borrello MA, Smith E, Cutler CW, Sojar H, Zauderer M. Prior exposure of mice to Fusobacterium nucleatum modulates host response to Porphyromonas gingivalis. Oral Microbiol Immunol 2001;16:338-44. (Pubitemid 33066029)
62. Reddy S, Kaul S, Asutkar H, Bhowmik N, Amudha. Host modulation in periodontics. e-Journal of Dentistry 2011;1:51-62.
63. La VD, Howell AB, Grenier D. Cranberry proanthocyanidins inhibit MMP production and activity. J Dent Res 2009;88:627-32.
64. Bodet C, Chandad F, Grenier D. Cranberry components inhibit interleukin-6, interleukin-8, and prostaglandin E production by lipopolysaccharide-activated gingival fibroblasts. Eur J Oral Sci 2007;115:64-70.
65. Venezia E, Goldstein M, Boyan BD, Schwartz Z. The use of enamel matrix derivative in the treatment of periodontal defects: A literature review and meta-analysis. Crit Rev Oral Biol Med 2004;15:382-402. (Pubitemid 44567523)
66. Hammarström L, Heijl L, Gestrelius S. Periodontal regeneration in a buccal dehiscence model in monkeys after application of enamel matrix proteins. J Clin Periodontol 1997;24:669-77. (Pubitemid 127731609)
67. Hammarström L. Enamel matrix, cementum development and regeneration. J Clin Periodontol 1997;24:658-68. (Pubitemid 127731608)
68. Heijl L, Heden G, Svardström G, Ostgren A. Enamel matrix derivative (Emdogain) in the treatment of intrabony periodontal defects. J Clin Periodontol 1997;24:705-14. (Pubitemid 127731614)
69. Lyngstadaas SP, Wohlfahrt JC, Brookes SJ, Paine ML, Snead ML, Reseland JE. Enamel matrix proteins; old molecules for new applications. Orthod Craniofac Res 2009;12:243-53.
70. Urist MR, Strates BS. The Classic: Bone Morphogenetic Protein. Clin Orthop Relat Res 2009;467:3051-62.
71. Chen FM, An Y, Zhang R, Zhang M. New insights into and novel applications of release technology for periodontal reconstructive therapies. J Control Release 2011;149:92-110.
72. Sood S, Gupta S, Mahendra A. Gene therapy with growth factors for periodontal tissue engineering-A review. Med Oral Patol Oral Cir Bucal 2012;17:e301-10.
73. Nevins M, Giannobile WV, McGuire MK, Kao RT, Mellonig JT, Hinrichs JE, et al. Platelet derived growth factor (rhPDGF-BB) stimulates bone fill and rate of attachment level gain, results of a large, multicenter randomized controlled trial. J Periodontol 2005;76:2205-15. (Pubitemid 43116085)
74. Mitsuta T, Horiuchi H, Shinoda H. Effects of topical administration of clodronate on alveolar bone resorption in rats with experimental periodontitis. J Periodontol 2002;73:479-86. (Pubitemid 34546397)
75. Houshmand B, Rahimi H, Ghanavati F, Alisadr A, Eslami B. Boosting effect of bisphosphonates on osteoconductive materials: a histologic in vivo evaluation. J Periodontal Res 2007;42:119-23.
76. Veena HR, Prasad D. Evaluation of an aminobisphosphonate (alendronate) in the management of periodontal osseous defects. J Indian Soc Periodontol 2010;14:40-5.
77. Zeshmukh J, Jawali MA, Kulkarni VK. Host modulation therapy-a promising new concept in treating periodontal diseases. Int J Dent Clin 2011:3:48-53.
78. Howell TH, Fiorellini J, Weber HP, Williams RC. Effect of the NSAID piroxicam, topically administered, on the development of gingivitis in beagle dogs. J Periodont Res 1991;26:180-3.
79. Kornman KS, Blodgett RF, Brunsvold M, Holt SC. Effects of topical applications of meclofenamic acid and ibuprofen on bone loss, subgingival microbiota and gingival PMN response in the primate Macaca fascicularis. J Periodont Res 1990;25:300-7. (Pubitemid 20329862)
80. Mainnemare A, Mégarbane B, Soueidan A, Daniel A, Chapple IL. Hypochlorous Acid and Taurine-N-Monochloramine in Periodontal Diseases. J Dent Res 2004;83:823-31. (Pubitemid 41756893)
81. Lorenz K, Mayer D, Bruhn G, Noack B, Brecx M, Heumann C, et al. Effect of N-chlorotaurine mouth rinses on plaque regrowth and plaque vitality. Clin Oral Investig 2009;13:9-14.
82. Hasturk H, Kantarci A, Ebrahimi N, Andry C, Holick M, Jones VL, et al. Topical H2 antagonist prevents periodontitis in a rabbit model. Infect Immun 2006;74:2402-14.